



SUMMARY OF DECISIONS – CCRVDF28

1. OBJECTIVE OF THE REPORT

This report provides a **consolidated overview of the main outcomes, decisions, and ongoing work** of the 28th session of CCRVDF, with the aim of supporting **national authorities of CCNE countries** in aligning their control systems with Codex developments.

2. EXECUTIVE SUMMARY

The 28th session of the Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF28) resulted in targeted progress on MRLs, introduction of new risk management tools, and reinforcement of science-based decision-making, while highlighting persistent constraints related to data availability and procedural timelines:

- The Committee advanced MRLs for selected substances, notably through extrapolation to camelids (e.g. tetracyclines and ivermectin in milk), and forwarded them for adoption by CAC. At the same time, it adopted a precautionary approach for fumagillin (DCH), maintaining MRLs at Step 7 pending JECFA re-evaluation, due to scientific uncertainties and concerns regarding compatibility with Good Veterinary Practice.
- A major outcome was the advancement of Action Levels (ALs) for Nicarbazin and Lasalocid in eggs, marking a shift toward risk-based operational tools to address unavoidable carryover in feed. The Committee also progressed guidance on carryover, reinforcing the need to distinguish between unintentional contamination and non-compliant use.
- CCRVDF28 further agreed on an updated priority list of veterinary drugs for JECFA evaluation, establishing a pipeline for future MRL development. However, the session emphasized critical challenges, including insufficient data for several compounds, delays between scientific advice and standard-setting, and limited capacity and funding for JECFA activities.

For CCNE countries, key implications include the need to:

CCNE countries should strengthening active participation in Codex work (EWGs and PWGs) to influence future standards. This requires enhanced data generation and submission to JECFA, improved coordination at regional level, and adoption of risk-based control approaches, positioning CCNE not only as implementers but as contributors to international standard-setting.

3. MAIN OUTCOMES AND DECISIONS

Agenda Item	Main conclusion	
Item 6 – MRLs for fumagillin (DCH)	<ul style="list-style-type: none"> ✓ Recalled that the MRLs could not be advanced; ✓ Agreed to retain them at Step 7 pending JECFA re-evaluation. <ul style="list-style-type: none"> -Outstanding scientific concerns remained regarding the suitability of the marker residue and residue depletion data. -Additional toxicological/residue clarification from JECFA was considered necessary before final adoption. 	
Item 7.1 – Extrapolated MRLs (camelids)	<ul style="list-style-type: none"> ✓ Agreed to advance extrapolated MRLs to CAC49 at Step 5/8: codex criteria were sufficiently met (similar metabolism, residue behavior, marker residue relationships, comparable edible tissues). <ul style="list-style-type: none"> • Ivermectin in camelids (milk) (milk): 10 µg/kg • Tetracyclines (chlortetracycline, oxytetracycline, and tetracycline): <ul style="list-style-type: none"> – Muscle: 200 µg/kg – Liver: 600 µg/kg – Kidney: 1200 µg/kg – Milk: 100 µg/kg • To forward the editorial amendments to CXM 2 (Appendix IV) to CAC49 for adoption ✓ Agreed not to extrapolate substances: albendazole, ivermectin (tissues) as criteria were not met. 	
Item 7.2 – Extrapolation to other edible offal	<ul style="list-style-type: none"> ✓ CCRVDF28 agreed on general conditions and further work (pilot approach). <ul style="list-style-type: none"> ◆ Pilot substances: Oxytetracycline, Ceftiofur and Ivermectin ✓ An EWG (UK, Costa Rica, USA) was established to: <ul style="list-style-type: none"> • implement the pilot and assess data requirements, species, uses, and exposure; • refine extrapolation conditions based on results; • clarify terminology and use of extrapolated values; • consider implications for guidance development and CCPR harmonization; ✓ review cross-species extrapolation proposals. 	
Item 8.1 – Carryover guidance	<p>CCRVDF28 agreed to advance draft guidelines to Step 5/8 (with omission of Steps 6 and 7).</p> <ul style="list-style-type: none"> ◆ Risk-based approach ◆ Tools: RRS, RMDT 	
Item 8.2 – Action Levels (ALs)	<p>CCRVDF28 agreed to advance ALs to Step 5/8 for adoption by CAC.</p> <ul style="list-style-type: none"> ◆ Nicarbazin (DNC) – eggs: 0.35 mg/kg ◆ Lasalocid – eggs: 0.15 mg/kg 	
Item 9 – Coordination CCPR/CCRVDF	<p>CCRVDF28 encouraged Members to participate in joint EWG and coordination activities.</p>	
Item 10 – Priority list for JECFA evaluation	<ul style="list-style-type: none"> ✓ Forward parts I, IV and V the priority list of veterinary drugs as amended to CAC49 (2026) for approval as new work; ✓ Forward the revised “Template for information recommended for consideration in the priority list by the 	<ul style="list-style-type: none"> ◆ Part I (JECFA evaluation): <ul style="list-style-type: none"> • Amoxicillin (chicken tissues, eggs) • Doramectin (cattle tissues) • Ketoprofen (cattle tissues) • Pradofloxacin (cattle, pigs) • Ethion (delayed)

	<p>Codex Committee on Residues of Veterinary Drugs in Foods” for adoption by CAC49 as an editorial amendment to Annex A of the Risk analysis principles applied by CCRVDF;</p> <p>✓ Forward the new nomination template for Part V “Veterinary drug for extrapolation of MRLs to one or more species” for approval by CAC49 as an editorial amendment to Annex A of the Risk analysis principles applied by CCRVDF; and</p> <p>✓ Establish a PWG, chaired by Australia, to consider the replies to a CL requesting comments and information on the priority list of veterinary drugs requiring evaluation or re-evaluation by JECFA and other parts of the priority list.</p>	<ul style="list-style-type: none"> • Fumajillin ⇨ Part IV (parallel review) Evaluation of a new compound: <ul style="list-style-type: none"> • Umifoxolaner (cattle) • Bromoform (ruminants) ⇨ Part V (extrapolation): <ul style="list-style-type: none"> • Abamectin • Dexamethasone • Doramectin • Eprinomectin • Febantel / Fenbendazole / Oxfendazole • Sulfadimidine • Tylosin
--	--	---

4. PLANNED ACTIVITIES AND FOLLOW-UP WORK (POST-CCRVDF28)

Following the conclusions of CCRVDF28, the Committee agreed on a comprehensive program of intersessional activities aimed at advancing ongoing technical work, strengthening the scientific basis for decision-making, and ensuring continuity in the development of Codex standards.

These activities are primarily implemented through Physical and Electronic Working Groups (PWGs/EWGs), as well as joint initiatives with other Codex committees (notably CCPR). They focus on key priorities including the update of the JECFA priority list, the refinement of extrapolation methodologies, and the harmonization of approaches for dual-use compounds.

In addition, Members and EWG Chairs are expected to play an active role in ensuring the effectiveness of this work through timely submission of documents, provision of scientific data, and participation in technical discussions.

Table 2: Summary of planned activities and responsibilities

Agenda Item (CCRVDF28)	Responsible Party	Purpose / Process	Subject / Output (including values)
Item 6 – Fumagillin (DCH)	JECFA/CCRVDF29	Evaluation/scientific advice	JECFA evaluation : MRLs for fumagillin (fish fillet, honey) retained at Step 7 (not adopted)
Item 7.1 – Extrapolation of MRLs (camelids)	CCEXEC90 / CAC49	Critical review / Adoption	MRLs extrapolated for camelids: <ul style="list-style-type: none"> • Ivermectin (milk): 10 µg/kg • Tetracyclines (sum):- Muscle: 200 µg/kg– Liver: 600 µg/kg– Kidney: 1200 µg/kg– Milk: 100 µg/kg
	CCEXEC90 / CAC49	Critical review / Adoption	Editorial amendments to CXM 2 (harmonisation of tetracyclines naming)
Item 7.2 – Extrapolation to	EWG (UK, Costa Rica, USA) / CCRVDF29	Discussion / Consideration	Pilot study (tetracyclines, ceftiofur, ivermectin) + refinement of criteria, exposure approach and terminology

other edible offal tissues		Discussion / Consideration	Pilot study (tetracyclines, ceftiofur, ivermectin) + refinement of criteria, exposure approach and terminology
Item 8.1 – Carryover guidance	CCEXEC90 / CAC49	Critical review / Adoption	Guidelines on risk-based actions for carryover (absence of Codex MRL; use of RRS, RMDT)
	CCEXEC90 / CAC49	Critical review / Adoption	Action Levels in eggs:• Nicarbazin (DNC): 0.35 mg/kg (350 µg/kg)• Lasalocid: 0.15 mg/kg (150 µg/kg)
Item 9 – CCPR/CCRVDF coordination	Joint EWG (USA, Brazil) / CAC49	Discussion / Coordination	Harmonisation of food descriptors and dual-use MRLs
Item 10 – Procedural Manual / priority list templates	CCEXEC90 / CAC49	Critical review / Adoption	Amendments to Codex Procedural Manual (Annex A):• Updated priority list template• New template for extrapolation (Part V)
Item 10 – Priority list (approval)	CCEXEC90 / CAC49	Critical review / Approval	Priority list of veterinary drugs for JECFA evaluation (e.g. amoxicillin, doramectin, ketoprofen, pradofloxacin, etc.)
Item 10 – JECFA evaluation	JECFA	Scientific advice	Evaluation of priority compounds leading to future MRL proposals
Item 10 – Follow-up priority list	PWG on Priorities (Australia) / CCRVDF29	Comments / Consideration	Review of responses to Circular Letter on priority list

5. KEY IMPLICATIONS FOR CCNE

Activity / Workstream	Agenda Item	Type (Adoption / EWG / PWG / JECFA)	Objective for Authorities	Key Actions Required	Priority Level
Adoption of MRLs (camelids)	Item 7.1	Adoption (CAC49)	Align national regulations with Codex MRLs	<ul style="list-style-type: none"> Update national MRL framework Adapt control plans 	● High
Implementation of Action Levels (eggs)	Item 8.2	Adoption (CAC49)	Introduce ALs as screening tools	<ul style="list-style-type: none"> Integrate ALs in monitoring Train inspectors 	● High
Carryover guidance	Item 8.1	Adoption / Guidance	Apply risk-based interpretation of residues	<ul style="list-style-type: none"> Implement RRS/RMDT Training sessions for adoption and update SOPs 	● High
Fumagillin (DCH) follow-up	Item 6	Scientific / CCRVDF29	Monitor re-evaluation and prepare position	<ul style="list-style-type: none"> Collect national data Define position 	● Medium

Extrapolation pilot (offal)	Item 7.2	EWG	Influence extrapolation criteria	• Participate in EWG • Provide data (tetracyclines, ivermectin)	● High
Priority list (JECFA)	Item 10	PWG	Influence future MRLs	• Submit proposals • Coordinate CCNE inputs	● High
JECFA data submission	Item 10	Scientific	Support evaluation of compounds	• Generate residue data • Submit data	● High
CCPR/CCRVDf harmonization	Item 9	Joint EWG	Align dual-use compounds	• Participate in joint EWG • Coordinate pesticide/vet sectors	● Medium

6. RECOMMENDATIONS ON ENGAGEMENT IN ONGOING WORK PLANNED BY CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS (CCRVDf28)

Countries are strongly encouraged to actively engage in the follow-up activities arising from CCRVDf28, with particular emphasis on contributing to technical work and regional coordination efforts. In this context, the following recommendations are proposed:

- **Participation in future working groups:** Countries are invited to take part in upcoming electronic and physical working groups, notably those related to the *pilot work on extrapolation to offal tissues*. A formal invitation and registration details will be circulated once the work is officially launched.
- **Strengthening regional coordination:** It is recommended to initiate dedicated coordination meetings and technical consultations within the CCNE framework to develop consolidated regional proposals and inputs (notably related to the priority list to be considered for JECFA evaluation), ensuring effective and timely contributions to the physical working groups.

These actions will support proactive engagement, enhance regional alignment, and ensure that CCNE countries effectively contribute to shaping future Codex guidance and standards.

